Gender Dysphoria

Clinical picture

• Marked incongruence between experienced gender and assigned sex, present at least 6 months and expressed with consistency and insistence.
• Distress commonly localizes to specific sex characteristics: chest, voice, facial and body hair, menses, genitals, and body habitus.
• Puberty frequently intensifies dysphoria sharply, converting tolerable discomfort into acute distress and functional collapse.
• Presentation may be masked by depression, anxiety, self-harm, substance use, or eating pathology aimed at altering body shape.
• Being transgender or gender diverse is not a mental disorder; distress and impairment, not identity, define this diagnosis.
• Many gender diverse people never meet criteria, and dysphoria often resolves substantially with social and medical affirmation.

Criteria snapshot

• Adolescents and adults require at least 2 of 6 indicators over at least 6 months, with clinically significant distress or impairment.
• Adult indicators include incongruence with one's sex characteristics, wanting to be rid of or to acquire them, and wanting to be treated as another gender.
• Children require at least 6 of 8 indicators over 6 months, and a strong stated desire to be another gender is mandatory among them.
• Child indicators cover cross-gender role play, toy and playmate preferences, rejection of assigned-gender clothing, and dislike of one's anatomy.
• Specifiers note a co-occurring disorder of sex development and posttransition status when affirming treatment is established.

Neurobiology

• Gender identity has partly biological determinants; twin studies estimate heritability of gender incongruence at roughly 30-60%.
• Prenatal androgen exposure influences gendered behavior, seen in elevated rates of gender variance in congenital adrenal hyperplasia.
• Reported differences in the bed nucleus of the stria terminalis and INAH3 exist but are not diagnostic or clinically usable.
• No biological test establishes or refutes gender identity; diagnosis rests entirely on the person's self-reported experience.
• Gender-affirming hormone therapy produces the expected somatic changes and, in cohort studies, marked reductions in dysphoria and depression.
• Monitoring targets bone density, lipids, hematocrit on testosterone, and venous thromboembolism risk on estrogen therapy.

Psychology

• Minority stress explains most excess psychiatric morbidity: discrimination, rejection, concealment, and internalized transphobia.
• Family acceptance is the strongest modifiable protective factor, reducing rates of depression and suicide attempt severalfold.
• Chest binding, tucking, restrictive eating, and body avoidance manage dysphoria short term at real physical and functional cost.
• Use of the affirmed name and pronouns in even one setting is associated with substantially lower suicidal ideation in youth.
• Conversion or reparative efforts to change gender identity are ineffective and harmful and are rejected by every major professional body.

Differential & comorbidity

• Distinguish from gender nonconformity without distress, transvestic disorder, body dysmorphic disorder, and psychosis-driven beliefs.
• Depression, anxiety, PTSD, and substance use disorders are elevated and largely reflect stigma and victimization, not the identity.
• Autism spectrum disorder co-occurs at several times the base rate; it does not invalidate gender identity or preclude affirming care.
• Screen actively for suicidality, self-harm, homelessness, survival sex work, and violence victimization at every encounter.
• Eating disorders are common and may serve gender goals such as suppressing menses or altering curves; ask about motive directly.

Pharmacologic treatment

• GnRH agonists such as leuprolide or histrelin pause puberty from Tanner stage 2 and are largely reversible, per Endocrine Society guidance.
• Feminizing therapy uses estradiol with an antiandrogen such as spironolactone; monitor estradiol, potassium, and VTE risk.
• Masculinizing therapy uses testosterone by injection or gel; monitor hematocrit, lipids, blood pressure, and menstrual cessation.
• Discuss fertility preservation before starting blockers or hormones, since gonadal function may not fully recover afterward.
• Treat comorbid depression and anxiety on their own merits; affirming care itself often reduces symptom burden substantially.

Psychotherapy

• Gender-affirming psychotherapy explores identity without a predetermined destination and never aims to change gender identity.
• WPATH SOC-8 replaces gatekeeping with assessment of capacity for informed consent and management of coexisting conditions.
• CBT and DBT address depression, anxiety, and self-harm and build distress tolerance around body-related triggers.
• Family therapy that moves caregivers from rejection toward acceptance is among the highest-yield interventions available.
• Peer and group support reduces isolation and internalized stigma; refer to vetted local and online community resources.

Adjunct options

• Social transition covers name, pronouns, clothing, hair, voice, and documents, is reversible, and typically comes first.
• Surgical options include chest, genital, facial, and voice procedures, coordinated under SOC-8 readiness criteria.
• Voice and communication therapy, hair removal, and prosthetics address dysphoria that hormones alone do not resolve.
• ICD-11 renamed the construct gender incongruence and moved it out of the mental disorders chapter to reduce stigma.
• The DSM diagnosis is retained largely to secure insurance coverage and access to medically necessary gender-affirming care.

Clinical pearls

• The identity is not the disorder; the distress is, and affirming care usually relieves it.
• Family acceptance and affirmed name use are the strongest protective factors for youth.
• Conversion efforts are harmful, ineffective, and condemned by every major medical body.